ClotShield provides an automated blood testing platform designed to detect and monitor pulmonary embolism risk in hospitalized patients. The system automates blood draws and testing to increase the frequency of clotting-risk assessments, enabling more current treatment plans and improved patient outcomes. This approach addresses the limitations of manual, expensive diagnostic methods that currently fail to catch dangerous clots.
Funding
Funding not disclosed
Founders
Product
Problem
Pulmonary embolism (PE), a clot in the lungs, is the leading cause of preventable hospital death, killing at least 10,000 people in US hospitals annually. Current diagnostic methods are too manual and expensive to support adequate monitoring, leaving many patients at risk of undetected clots.
Solution
ClotShield offers an automated blood testing platform that streamlines the detection and monitoring of clotting risk in hospital settings. The system automates both the blood draw and testing process, enabling more frequent assessments of patient clotting status without adding significant manual burden on clinical staff. By increasing testing frequency, ClotShield provides clinicians with more current data to guide treatment plans for clotting disorders. This proactive approach aims to catch dangerous clot formation earlier and improve patient outcomes while freeing up provider time.
Target Audience
Primary customers are hospitals and healthcare providers seeking to improve in-patient monitoring for pulmonary embolism and other clotting disorders.
Features
- Automated blood draw capability that reduces manual phlebotomy workload
- Automated blood testing system that enables frequent, routine clotting-risk assessments
- Improved patient outcomes through more current and actionable treatment plans
- Increased provider time by reducing manual diagnostic steps
- Predictive technology designed to identify clotting diseases effectively